 | |
| Company type | Aktiengesellschaft |
|---|---|
| SIX: BION[1] FWB: BBZA[2] | |
| Industry | Investment company |
| Founded | not a number value [3] |
| Headquarters | Schaffhausen, Switzerland[4] |
Key people | Thomas von Planta (Chairman)[5] |
| Products | Investment in biotechnology companies |
| Services | Investment company |
 CHF –206.6 million(2023)[6] | |
| Total assets | CHF 2.637 billion (2023)[6] |
| Website | www.bbbiotech.ch |
BB Biotech AG is a Swiss investment company in the field of biotechnology. The company invests mainly in the United States and Western Europe[7] and is managed by Bellevue Asset Management, a division of Bellevue Group, which is listed on the Swiss Stock Exchange.[8]
It is one of the largest investment companies in the biotech sector.[9][10]
- ^ "BB Biotech AG". Reuters. Retrieved 2021-10-20.
- ^ "BB Biotech AG Equity". Börse Frankfurt. Retrieved 2021-10-20.
- ^ AG, DV Bern. "BB Biotech AG". Official Companies Register of the Canton of Schaffhausen (in German). Retrieved 2021-10-20.
- ^ "BB Biotech AG". Zentraler Firmenindex (in German). Retrieved 2021-10-20.
- ^ "Board of Directors". BB Biotech. Retrieved 2024-07-01.
- ^ a b "Annual Report 2023" (PDF). BB Biotech. 2024. Retrieved 2024-06-29.
- ^ "BB Biotech AG". Bloomberg. Retrieved 2022-01-08.
- ^ "BB Biotech AG, A leading biotech investor" (PDF). QuotedData. 2021-02-11. Retrieved 2024-07-01.
- ^ "Themenschwerpunkt: BB Biotech" [Main Theme: BB Biotech]. Wirtschaftswoche (in German). Retrieved 2024-06-29.
- ^ "Aktien-Rückblick: BB Biotech Boom, Boom, Biotech". Wirtschaftswoche (in German). 2021-02-12.